+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single Injection, Three Injection, Five Injection), By Region, And Segment Forecasts, 2019 - 2026

  • ID: 4396500
  • Report
  • May 2019
  • Region: Global
  • 155 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Anika Therapeutics, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Ferring B.V.
  • Fidia Farmaceutici S.P.A
  • LG Life Sciences Ltd
  • Salix Pharmaceuticals
  • MORE
The global viscosupplementation market size is expected to reach USD 7.1 billion by 2026, based on this report. It is projected to expand at a CAGR of 9.11% during the forecast period. The market is expected to observe an exponential growth attributed to the increasing incidence of osteoarthritis, wounds, gingivitis, and ulcers coupled with growing geriatric population.

Estimates published by the World Health Organization (WHO) suggest that the global population of the age group 65 years and above is anticipated to rise from 7% in 2000 to 16% in 2050. A consequence of this growth in geriatric population will be the rise in prevalence of obesity and osteoarthritis. Along with the growing preference for minimally invasive surgeries, a global increase in the target population is expected to significantly propel demand for viscosupplementations throughout the forecast period.

Further key findings from the study suggest:
  • Three injections segment led the market in 2018, closely followed by the single injection segment. This growth can be accredited to the prolonged presence and holding a significant market share
  • Single injection segment is anticipated to be one of the fastest growing segments owing to the benefits of the product such as increased convenience and reduced hospital visits and adverse effects such as pain
  • Geographically, Asia Pacific held the largest market share in 2018 and is expected to maintain its position during the forecast period, owing to the presence of a sizeable geriatric population, which is more susceptible to disorders such as osteoarthritis and rheumatoid arthritis. Moreover, the growing demand for minimally invasive procedures is a significant factor contributing to the regional growth
  • Due to the presence of high unmet medical needs, growing awareness about applications of minimally invasive techniques, and increasing disposable income, Europe viscosupplementation market is expected to grow at a lucrative CAGR in the forthcoming years
  • Some key industry contributors are Sanofi, Anika Therapeutics, Inc., Seikagaku Corporation, Zimmer Holdings Inc., Bioventus, Ferring B.V., Lifecore Biomedical, LLC, and LG Life Sciences Ltd

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Anika Therapeutics, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Ferring B.V.
  • Fidia Farmaceutici S.P.A
  • LG Life Sciences Ltd
  • Salix Pharmaceuticals
  • MORE
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis

Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Outlook
2.2.1 By Product
2.3 Competitive Insights

Chapter 3 Viscosupplementation Market Variables, Trends & Scope
3.1 Market lineage outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Segmentation and Scope
3.3 User Perspective Analysis
3.3.1 Consumer Behaviour Analysis
3.3.2 Market Influencer Analysis
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing prevalence of osteoarthritis among geriatric population
3.4.1.2 New product development
3.4.1.2.1 Some of the recently launched products are as follows
3.4.2 Market Restraint Analysis
3.4.2.1 High cost and side effects associated with hyaluronic acid cycles
3.5 Viscosupplementation: Market Analysis Tools
3.5.1 Industry Analysis - Porter’s
3.5.2 Viscosupplementation Market - Pestle Analysis
3.5.3 Major Deals & Strategic Alliances Analysis
3.5.3.1 Joint ventures, mergers & acquisition
3.5.3.2 Licensing & partnership, technology collaborations
3.6 Penetration & Growth Prospects Mapping

Chapter 4 Viscosupplementation Market: Product Estimates & Trend Analysis
4.1 Viscosupplementation Market: Product Movement Analysis
4.2 Single Injection
4.2.1 Single-Injection Market Estimates And Forecasts, 2015 - 2026 (USD Million)
4.3 Three Injection
4.3.1 Three-Injection Market Estimates And Forecasts, 2015 - 2026 (USD Million)
4.4 Five Injection
4.4.1 Five-Injection Market Estimates And Forecasts, 2015 - 2026 (USD Million)
4.5 Product Information
4.5.1 Durolane
4.5.2 Gelsyn-3
4.5.3 Genvisc 850
4.5.4 Hymovis
4.5.5 Supartz Fx
4.5.6 Trivisc
4.5.7 Visco-3
4.5.8 Ostenil
4.5.9 Adant

Chapter 5 Viscosupplementation Market: Regional Estimates & Trend Analysis, by Product
5.1 Regional Market Dashboard
5.2 Viscosupplementation Market Share, by Region, 2018 & 2026
5.3 Regional Market Share Analysis, 2018 & 2026
5.4 SWOT Analysis, by Factor
5.4.1 North America
5.4.2 Europe
5.4.3 Asia Pacific
5.4.4 Latin America
5.4.5 Middle East & Africa
5.5 North America
5.5.1 U.S.
5.5.1.1 Regulatory and reimbursement scenario
5.5.1.2 U.S. viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.5.2 Canada
5.5.2.1 Regulatory and reimbursement scenario
5.5.2.2 Canada viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.6 Europe
5.7 Prices of Products in Europe
5.7.1 U.K.
5.7.1.1 Regulatory and reimbursement Scenario
5.7.1.2 U.K. viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.7.2 France
5.7.2.1 Regulatory and reimbursement scenario
5.7.2.2 France viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.7.3 Germany
5.7.3.1 Regulatory and reimbursement scenario
5.7.3.2 Germany viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.7.4 Italy
5.7.4.1 Regulatory and reimbursement scenario
5.7.4.2 Italy viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.7.5 Spain
5.7.5.1 Regulatory and reimbursement scenario
5.7.5.2 Spain viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.8 Asia Pacific
5.8.1 Asia Pacific Viscosupplementation Market Estimates And Forecasts, 2015 - 2026 (USD Million)
5.8.2 China
5.8.2.1 Regulatory and reimbursement scenario
5.8.2.2 China viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.8.3 Japan
5.8.3.1 Regulatory and reimbursement scenario
5.8.3.2 Japan viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.8.4 India
5.8.4.1 Regulatory and reimbursement scenario
5.8.4.2 India viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.8.5 South Korea
5.8.5.1 Regulatory and reimbursement scenario
5.8.5.2 South Korea viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.8.6 Australia
5.8.6.1 Regulatory and reimbursement scenario
5.8.6.2 Australia viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.9 Latin America
5.9.1 Regulatory And Reimbursement Scenario
5.9.2 Latin America Viscosupplementation Market Estimates And Forecasts, 2015 - 2026 (USD Million)
5.9.3 Brazil
5.9.3.1 Regulatory and reimbursement scenario
5.9.3.2 Brazil viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.9.4 Mexico
5.9.4.1 Regulatory and reimbursement scenario
5.9.4.2 Mexico viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.9.5 Argentina
5.9.5.1 Regulatory and reimbursement scenario
5.9.5.2 Argentina viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.9.6 Colombia
5.9.6.1 Colombia viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.10 MEA
5.10.1 MEA Viscosupplementation Market Estimates And Forecasts, 2015 - 2026 (USD Million)
5.10.2 South Africa
5.10.2.1 Regulatory and reimbursement scenario
5.10.2.2 South Africa viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.10.3 Saudi Arabia
5.10.3.1 Regulatory and reimbursement scenario
5.10.3.2 Saudi Arabia viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)
5.10.4 UAE
5.10.4.1 Regulatory and reimbursement scenario
5.10.4.2 UAE viscosupplementation market estimates and forecasts, 2015 - 2026 (USD Million)

Chapter 6 Reimbursement Outlook
6.1 Direct Medical Costs of Treatment of Osteoarthritis (Percentage Distribution)
6.2 Costs of Products
6.3 Reimbursement by Product
6.3.1 Gel-One
6.3.2 Euflexxa
6.3.3 Synvisc-One
6.3.4 Supartz
6.3.5 Hyalgan
6.3.6 Monovisc
6.3.7 Orthovisc

Chapter 7 Competitive Landscape
7.1 Clinical Pipeline
7.2 Clinical Trials
7.3 Recent Developments & Impact Analysis, By Key Market Participants
7.4 Vendor Landscape
7.4.1 List of key distributors and channel partners
7.5 Viscosupplement Competitive Landscape: Market Position Analysis (Based on products, regional presence)
7.6 Strategy Framework
7.7 Company Profiles
7.7.1 Sanofi
7.7.1.1 Company overview
7.7.1.2 Financial performance
7.7.1.3 Product benchmarking
7.7.1.4 Strategic initiatives
7.7.1.5 SWOT analysis
7.7.2 Anika Therapeutics, Inc.
7.7.2.1 Company overview
7.7.2.2 Financial performance
7.7.2.3 Product benchmarking
7.7.2.4 Strategic initiatives
7.7.2.5 SWOT analysis
7.7.3 Seikagaku Corporation
7.7.3.1 Company overview
7.7.3.2 Financial performance
7.7.3.3 Product benchmarking
7.7.3.4 Strategic initiatives
7.7.3.5 SWOT analysis
7.7.4 Zimmer Biomet
7.7.4.1 Company overview
7.7.4.2 Financial performance
7.7.4.3 Product benchmarking
7.7.4.4 Strategic initiatives
7.7.4.5 SWOT analysis
7.7.5 Smith & Nephew PLC
7.7.5.1 Company overview
7.7.5.2 Financial performance
7.7.5.3 Product benchmarking
7.7.5.4 Strategic initiatives
7.7.5.5 SWOT analysis
7.7.6 Ferring B.V.
7.7.6.1 Company overview
7.7.6.2 Financial performance
7.7.6.3 Product benchmarking
7.7.6.4 Strategic initiatives
7.7.7 Lifecore Biomedical, LLC (Landec)
7.7.7.1 Company overview
7.7.7.2 Financial performance
7.7.7.3 Product benchmarking
7.7.7.4 Strategic initiatives
7.7.7.5 SWOT analysis
7.7.8 LG Life Sciences Ltd
7.7.8.1 Company overview
7.7.8.2 Financial performance
7.7.8.3 Product benchmarking
7.7.8.4 Strategic initiatives
7.7.8.5 SWOT analysis
7.7.9 Salix Pharmaceuticals
7.7.9.1 Company overview
7.7.9.2 Financial performance
7.7.9.3 Product benchmarking
7.7.9.4 Strategic initiatives
7.7.9.5 SWOT analysis
7.7.10 Fidia Farmaceutici S.P.A
7.7.10.1 Company overview
7.7.10.2 Financial performance
7.7.10.3 Product benchmarking
7.7.10.4 Strategic initiatives
7.7.11 F.Hoffmann-La Roche Ltd.
7.7.11.1 Company overview
7.7.11.2 Financial performance
7.7.11.3 Product benchmarking
7.7.11.4 Strategic initiatives
7.7.11.5 SWOT analysis

Chapter 8 Recommendations

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi
  • Anika Therapeutics, Inc.
  • Seikagaku Corporation
  • Zimmer Biomet
  • Smith & Nephew PLC
  • Ferring B.V.
  • Lifecore Biomedical, LLC (Landec)
  • LG Life Sciences Ltd
  • Salix Pharmaceuticals
  • Fidia Farmaceutici S.P.A
  • F.Hoffmann-La Roche Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll